Reductions in the expression of PGC-1α have been consistently observed in the striatum and muscle of patients with HD [15]–[18], potentially due to pathogenic interactions of mHtt with the PGC-1α promoter [15]. This evidence concerns the gene PPARGC1A and Huntington disease.